<PAGE>
================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

       [X]      QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
                EXCHANGE ACT OF 1934

                For the quarterly period ended June 30, 2003

       [ ]      TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

                 For the transition period from             to
                                                -----------    -----------

                             LARK TECHNOLOGIES, INC.
        (Exact name of small business issuer as specified in its charter)


                  DELAWARE                                      73-1461841
         (State or other jurisdiction of                      (IRS Employer
         Incorporation or organization)                     Identification No.)

                 9441 WEST SAM HOUSTON PARKWAY SOUTH, SUITE 103
                                HOUSTON, TX 77099
                    (Address of principal executive offices)

                                 (713) 779-3663
                           (Issuer's telephone number)


Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes [X] No [ ]

                APPLICABLE ONLY TO ISSUER INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant filed all documents and reports required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of
securities under a plan confirmed by a court. Yes [ ] No [ ]


                      APPLICABLE ONLY TO CORPORATE ISSUERS

As of August 5, 2003, there were 3,685,137 shares of Common Stock, par value
$0.001 per share, outstanding.

Transitional Small Business Disclosure Format (Check one): Yes [ ] No [X]

================================================================================

<PAGE>

                             LARK TECHNOLOGIES, INC.

                              INDEX TO FORM 10-QSB
                      FOR THE QUARTER ENDED JUNE 30, 2003.


<Table>
<Caption>
Part I   Financial Information (unaudited)
                                                                                  Page
                                                                                  ----
<S>                                                                               <C>
       Item 1.    Financial Statements

                      Balance Sheet ............................................    1

                      Statements of Operations .................................    2

                      Statements of Cash Flows .................................    3

                      Notes to Financial Statements ............................    4

       Item 2.    Management's Discussion and Analysis of
                  Financial Condition and Results of Operations ................    7

       Item 3.  Controls and Procedures ........................................    9


Part II  Other Information .....................................................    9

       Item 1.    Legal Proceedings ............................................    9

       Item 2.    Changes in Securities ........................................    9

       Item 3.    Defaults upon Senior Securities ..............................    9

       Item 4.    Submission of Matters to a Vote of Security Holders ..........    9

       Item 5.    Other Information ............................................    9

       Item 6.    Exhibits and Reports on Form 8-K .............................    9

Signatures .....................................................................   11

Certifications .................................................................   12
</Table>

                                       i

<PAGE>


                         PART I - FINANCIAL INFORMATION
                          ITEM 1. FINANCIAL STATEMENTS
                             LARK TECHNOLOGIES, INC.
                                  BALANCE SHEET

<Table>
<Caption>
                                                                            June 30, 2003
                                                                            -------------
                                                                            (Unaudited)
<S>                                                                         <C>
ASSETS
Current assets:
            Cash and cash equivalents                                       $     848,351
            Accounts receivable, net                                        $   1,716,411
            Due from related parties                                        $      17,206
            Inventory                                                       $     155,601
            Prepaid expenses                                                $      88,503
                                                                            -------------
Total current assets                                                        $   2,826,072

Property and equipment, net                                                 $   2,227,070
Other assets, net                                                           $      77,931
                                                                            -------------
Total assets                                                                $   5,131,073
                                                                            =============

LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities:
            Accounts payable                                                $     440,758
            Capital lease obligations-current portion                       $     508,144
            Accrued expenses                                                $     245,169
            Customer deposits                                               $     414,712
                                                                            -------------
Total current liabilities                                                   $   1,608,783


Capital lease obligations-long term portion                                 $     662,507
Deferred rent expense                                                       $      37,206
                                                                            -------------
Total liabilities                                                           $   2,308,496

Stockholders' equity
            Preferred stock, $0.001 par value:
              Authorized shares - 2,000,000
              None issued and outstanding -
            Common stock, $0.001 par value:
              Authorized shares - 8,000,000
              Issued shares: 3,881,017 and outstanding shares:3,650,137     $       3,881
            Additional paid-in capital                                      $   3,093,878
            Treasury stock at cost                                          $    (412,988)
            Deferred compensation                                           $      (4,144)
            Accumulated other comprehensive income                          $      39,656
            Retained earnings                                               $     102,294
                                                                            -------------
Total stockholders' equity                                                  $   2,822,577
                                                                            -------------
Total liabilities and stockholders' equity                                  $   5,131,073
                                                                            =============
</Table>

See accompanying notes to the financial statements.


                                       1
<PAGE>


                             LARK TECHNOLOGIES, INC.
                            STATEMENTS OF OPERATIONS

<Table>
<Caption>
                                          Three months Ended June 30,    Six months Ended June 30,
                                          ---------------------------    --------------------------
                                              2002           2003            2002           2003
                                          -----------     -----------    -----------    -----------
                                                 (Unaudited)                   (Unaudited)
<S>                                       <C>            <C>             <C>            <C>
Revenue:
      Laboratory services                 $ 1,911,066     $ 2,284,038    $ 3,392,065    $ 4,401,136

Costs and expenses:
      Costs of services                       914,606       1,097,185      1,785,735      2,133,494
      Sales, general and administrative       585,775         613,944      1,050,021      1,221,983
                                          -----------     -----------    -----------    -----------
Total costs and expenses                    1,500,381       1,711,129      2,835,756      3,355,477
                                          -----------     -----------    -----------    -----------
Operating income                              410,685         572,909        556,309      1,045,659

Other income and (expense):
      Interest income                           1,208           1,525          2,740          3,109
      Other income                                                                            4,229
      Interest expense                        (14,399)        (22,244)       (33,329)       (45,939)
                                          -----------     -----------    -----------    -----------
Total other expense                           (13,191)        (20,719)       (30,589)       (38,601)
                                          -----------     -----------    -----------    -----------
Income before income taxes                    397,494         552,190        525,720      1,007,058

Provision for income taxes                          0          18,982         32,000         37,112
                                          -----------     -----------    -----------    -----------
Net income                                $   397,494     $   533,208    $   493,720    $   969,946
                                          ===========     ===========    ===========    ===========

Basic income per common share                    0.11            0.14           0.14           0.27
Diluted income per common share                  0.11            0.13           0.14           0.24
</Table>


See accompanying notes to the financial statements.


                                       2
<PAGE>


                             LARK TECHNOLOGIES, INC.
                            STATEMENTS OF CASH FLOWS

<Table>
<Caption>
                                                              Six Months ended June 30,
                                                              -------------------------
                                                                2002              2003
                                                              --------         --------
                                                                     (Unaudited)
<S>                                                           <C>              <C>
OPERATING ACTIVITIES
Net income                                                     493,720          969,946
Adjustments to reconcile net income to net
   cash provided by operating activities
               Depreciation and amortization                   217,299          270,464
               Amortization of deferred compensation                --              638
               Provision for bad debts                          10,630           12,760
               Changes in operating assets and liabilities:
                    Accounts receivable                       (137,376)        (379,476)
                    Inventory                                   75,952         (107,759)
                    Prepaid expenses and other assets           10,601           12,211
                    Due to/from related parties                (14,933)          13,492
                    Accounts payable                          (136,557)           3,770
                    Accrued expenses                            11,760           14,943
                    Deferred rent                                4,662               18
                    Customer deposits                            7,572          160,861
                                                              --------         --------
Net cash provided by operating activities                      543,330          971,868

INVESTING ACTIVITIES
Purchases of property and equipment                           (127,853)        (335,769)
                                                              --------         --------
Net cash used in investing activities                         (127,853)        (335,769)

FINANCING ACTIVITIES
Principal payments on notes payable                           (369,818)              --
Principal payments on capital leases                           (95,561)        (294,277)
Proceeds from exercised stock options                           15,625          402,320
Treasury stock                                                      --         (396,766)
                                                              --------         --------
Net cash used in financing activities                         (449,754)        (288,723)
Effect of currency translation on cash                              18            1,844
                                                              --------         --------
Net increase (decrease) in cash and cash equivalents           (34,259)         349,220
Cash and cash equivalents at beginning of period               414,242          499,131
                                                              --------         --------
Cash and cash equivalents at end of period                     379,983          848,351
                                                              ========         ========
</Table>


See accompanying notes to the financial statements.


                                       3
<PAGE>

                             LARK TECHNOLOGIES, INC.
                          NOTES TO FINANCIAL STATEMENTS
                                   (UNAUDITED)


1.       SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

         In the opinion of management, the accompanying unaudited interim
financial statements have been prepared in accordance with accounting principles
generally accepted in the United States and the rules and regulations of the
Securities and Exchange Commission. Certain information in footnote disclosures
normally included in financial statements prepared in accordance with accounting
principles generally accepted in the United States have been condensed or
omitted pursuant to these rules and regulations. The accompanying unaudited
interim financial statements reflect all adjustments which the Company considers
necessary for a fair presentation of the results of operations for the interim
periods covered and for the financial condition of the Company at the date of
the interim balance sheet. All such adjustments are of a recurring nature.
Results for the interim periods are not necessarily indicative of results for
the year.

Use of Estimates

         The preparation of financial statements in conformity with accounting
principles generally accepted in the United States requires management to make
judgments, estimates and assumptions that affect the amounts reported in the
financial statements and accompanying notes. Actual results could differ from
those estimates.

Revenue Recognition

         The Company recognizes revenue and related profit upon the completion
and shipment of laboratory service projects. For laboratory service projects
under long-term contracts, revenue and related profit is recognized as specific
projects are completed. Revenues include shipping costs billed to customers and
the related costs are recorded as cost of sales. Costs incurred on partially
completed projects are recorded as work-in-process.

Stock Options

         The Company generally grants stock options to its employees for a fixed
number of shares with an exercise price equal to the fair value of the shares on
the date of grant. As allowed under the Statement of Financial Accounting
Standards No. 123, "Accounting for Stock-Based Compensation" (SFAS 123), the
Company has elected to follow Accounting Principles Board Opinion No. 25,
"Accounting for Stock Issued to Employees" (APB 25) and related interpretations
in accounting for stock awards to employees. Accordingly, no compensation
expense is recognized in the Company's financial statements in connection with
stock options granted to employees with exercise prices not less than fair
value. Deferred compensation for options granted to employees is determined as
the difference between the deemed fair market value of the Company's common
stock on the date options were granted and the exercise price. For purposes of
this pro-forma disclosure, the estimated fair value of the options is assumed to
be amortized to expense over the options' vesting period. Compensation expense
for options granted to non-employees has been determined in accordance with FAS
123 as the fair value of the consideration received or the fair value of the
equity instruments issued.

     Pro forma information under SFAS 123 is as follows.


                                       4
<PAGE>

<Table>
<Caption>
                                         Three months ended          Six months ended
                                               June 30,                 June 30,
                                          2002        2003          2002          2003
                                        ---------   ---------     ---------     ---------
<S>                                     <C>         <C>           <C>           <C>
           Net income:
            As reported                 $ 397,494   $ 533,208     $ 493,720     $ 969,946
          Deduct: Total
               stock-based employee
               compensation expense
               determined under fair
               value method for all
               awards, net of related
               tax effects                (11,901)    (16,947)     (135,223)     (192,326)
                                        ---------   ---------     ---------     ---------

          Pro forma net income (loss)   $ 385,593   $ 516,261     $ 358,497     $ 777,620
                                        =========   =========     =========     =========

               Basic net income
                 per share:
                 As reported            $    0.11   $    0.14     $    0.14     $    0.27
                 Pro forma              $    0.11   $    0.14     $    0.10     $    0.21

               Diluted net income
                 per share:
                 As reported            $    0.11   $    0.13     $    0.14     $    0.24
                 Pro forma              $    0.11   $    0.12     $    0.10     $    0.20
</Table>


The fair value of these options was estimated at the date of grant using the
Black-Scholes option pricing ("Black-Scholes") model for the 2002 and 2003
options granted with the following weighted average assumptions:


<Table>
<Caption>
                                          Three months ended    Six months ended
                                               June 30,             June 30,
                                          2002          2003    2002        2003
                                          ----          ----    ----        ----
<S>                                       <C>           <C>     <C>         <C>
Volatility                                 .91          1.02     .91        1.02
Expected dividend yield                      0%            0%      0%          0%
Risk-free interest rate                    3.7%          3.1%    3.7%        3.1%
Expected life (years)                        5             5       5           5
</Table>

Impact of Recent Accounting Standard

         In January 2003, the Financial Accounting Standards Board (FASB) issued
Interpretation (FIN) 46, Consolidation of Variable Interest Entities. FIN 46
requires that unconsolidated variable interest entities be consolidated by their
primary beneficiaries. A primary beneficiary is the party that absorbs a
majority of the entity's expected losses or residual benefits. FIN 46 applies
immediately to variable interest entities created after January 31, 2003, and to
existing variable interest entities in the fiscal year beginning after June 15,
2003. The Company is currently in the process of evaluating the impact FIN 46
will have on its financial position and results of operations, if any.

2.       INVENTORY

         Inventory is work in process that includes the direct and indirect
costs associated with projects that were started but not yet completed at June
30, 2003. Direct costs include such items as the cost of labor, reagents and
supplies directly associated with each project. Indirect costs include such
items as general supplies, laboratory management, depreciation, and costs to
operate the lab. These costs are applied to each project on the basis of direct
labor hours incurred for the project, up to the point of measurement, such as
the end of an accounting period. At June 30, 2003, work in process inventory was
$155,601.


                                       5
<PAGE>


3.       NOTES PAYABLE

         At June 30, 2003, the Company had a revolving line of credit with a
bank that provided for maximum borrowings of $600,000. Under the terms of the
line, borrowings were to bear interest at the bank's prime rate (4.00% at June
30, 2003) plus 1.5%. The line of credit expired December 31, 2002 and was
renewed through December 31, 2003 with the same terms as the expiring line of
credit. The line of credit is secured by qualified accounts receivable of the
Company. At June 30, 2003, the Company had no amounts outstanding under this
line of credit. The borrowing base for this line of credit is equal to 80% of
certain accounts receivable that are no more than 90 days old. On June 30, 2003,
the Company had an available line of credit of $600,000. Under the terms of the
revolving line of credit agreement, the Company is required to maintain certain
financial ratios and a specific level of net worth. The Company was in
compliance with all required covenants at June 30, 2003.

4.       COMPREHENSIVE INCOME (LOSS)

         Accumulated other comprehensive income presented on the accompanying
balance sheet consists of foreign currency translation adjustments. Total
comprehensive income for the three and six month periods ended June 30, 2003 was
$570,482 and $987,394, respectively.

5.       EARNINGS PER SHARE

         The following table sets forth the weighted average shares outstanding
for the computation of basic and diluted earnings per share:


<Table>
<Caption>
                                                  For the three months ending     For the six months ending
                                                            June 30,                     June 30,
                                                     2002             2003          2002             2003
                                                  ---------         ---------     ---------       ---------
<S>                                               <C>               <C>           <C>             <C>
Weighted average common shares outstanding:       3,546,706         3,683,616     3,531,884       3,660,125
Dilutive securities - employee stock options:        70,775           550,012        80,071         444,156
                                                  ---------         ---------     ---------       ---------
Weighted average common shares outstanding
 Used for dilution:                               3,617,481         4,233,628     3,611,955       4,104,281
                                                  =========         =========     =========       =========
</Table>


                           No options were excluded from either the 2002 or 2003
calculations.

6.       SEGMENT INFORMATION

         The proportion of the Company's revenue by location is as follows for
the three and six month periods ended June 30, 2002 and 2003:

<Table>
<Caption>
                Three months ended         Six months ended
                     June 30,                  June 30,
                2002         2003         2002         2003
             ----------   ----------   ----------   ----------
<S>          <C>          <C>          <C>          <C>
Sales - US   $1,445,889   $1,515,318   $2,550,842   $3,032,391
        UK      465,177      768,720      841,223    1,368,745
             ----------   ----------   ----------   ----------
             $1,911,066   $2,284,038   $3,392,065   $4,401,136
</Table>

7.       SIGNIFICANT AGREEMENT

         On March 20, 2003, the Company entered into a capital lease for the
purchase of a new automated DNA sequencer for the US lab. Under the terms of the
36 months lease, the Company may purchase this equipment for a nominal amount at
the end of the lease.



                                       6
<PAGE>



ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

         The following discussion and analysis should be read in conjunction
with the Financial Statements and the accompanying Notes herein, and is
qualified entirely by the foregoing and by other more detailed financial
information appearing elsewhere.

BUSINESS OF LARK

         Lark is a leader in providing contract molecular biology services to
the pharmaceutical, biotechnology and agbio industries. Lark's services are used
worldwide by research organizations and drug development institutions to
accelerate their efforts in bringing products to the market. Lark's contract
research service portfolio consists of over a hundred different molecular
biology services in the areas of Nucleic Acid Extraction Services, DNA
Sequencing Services, Genetic Stability Testing Services, Gene Expression and
Detection Services, and Custom Molecular Biology Services. A highly trained and
educated scientific staff working in a facility that is compliant with the Food
and Drug Administration's Good Laboratory Practices (CFR Title 21, Part 58)
performs all of these services.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

         The Company's discussion and analysis of its financial condition and
results of operations are based upon its financial statements, which have been
prepared in accordance with accounting principles generally accepted in the
United States. The preparation of these financial statements requires the
Company to make estimates and judgments that affect the reported amounts of
assets, liabilities, revenues and expenses, and related disclosure of contingent
assets and liabilities. On an on-going basis, the Company evaluates these
estimates, including those related to customer bad debts, estimated useful lives
of property and equipment, and income taxes. The Company bases its estimates on
historical experience and on various other assumptions that are believed to be
reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. Actual results may differ from these
estimates.

         The Company believes the following critical accounting policies reflect
the more significant judgments and estimates used in the preparation of the
financial statements:

ALLOWANCE FOR DOUBTFUL ACCOUNTS--The Company maintains an allowance for doubtful
accounts for estimated losses resulting from the inability of our customers to
pay for laboratory service fees. The Company generally requires a deposit of
approximately 50% of the total anticipated billings prior to commencing work on
larger laboratory service projects. Historically, the Company has not
experienced significant bad debts. However, if the financial condition of the
Company's customers were to deteriorate rapidly, resulting in nonpayment, the
Company could be required to provide additional allowances for doubtful accounts
which would decrease net income in the period that this determination was made.

PROPERTY AND EQUIPMENT--Property and equipment relate primarily to laboratory
equipment and computer equipment. These costs are depreciated or amortized over
the estimated useful lives of the assets. If technology related to the
laboratory equipment or computer equipment was to rapidly change, the estimated
useful lives of existing equipment may be shortened. This would result in
accelerating depreciation and amortization expense, which would decrease net
income in the periods following such a determination. Additionally, effective
January 1, 2002, the Company periodically evaluates the costs of property and
equipment for impairment in accordance with Statement of Accounting Standards
No. 144, "Accounting for Impairment or Disposal of Long-Lived Assets." If events
or circumstances were to indicate that any of the long-lived assets might be
impaired, the Company would be required to analyze the estimated undiscounted
future cash flows from the applicable assets. If the carrying value of the asset
were less than the undiscounted cash flows, the Company would be required to
record an impairment loss, which would reduce net income, to the extent that the
carrying value of the asset exceeded fair value.

DEFERRED TAXES--The Company has recorded a valuation allowance to reduce net
deferred tax assets to zero as a result of the Company's cumulative loss
position and the uncertainty of the Company's ability to realize the net
deferred tax assets in the future. If the Company were able to realize the
deferred tax assets in the future, an adjustment to reduce the valuation
allowance would increase net income.

                                       7
<PAGE>

RESULTS OF OPERATIONS

         REVENUES. Gross revenues increased 20% from $1,911,066 to $2,284,038
for the three-month periods ended June 30, 2002 and 2003, respectively. Gross
revenues increased 30% from $3,392,065 to $4,401,136 for the six-month periods
ended June 30, 2002 and 2003 respectively. The increase in revenues for the
quarter was the result of increased sales in most services with the largest
growth occurring in the quick turnaround and high throughput sequencing
services.

         COSTS OF SERVICES. Costs of services consist primarily of labor and
laboratory supplies. Costs of services increased 20% from $914,606 to $1,097,185
for the three-month periods ended June 30, 2002 and 2003, respectively. Costs of
services increased 19% from $1,785,735 to $2,133,494 for the six-month periods
ended June 30, 2002 and 2003, respectively. The majority of the increase was a
result of increased sales revenue. Costs of services as a percentage of revenue
were 48% for each of the three-month periods ending June 30, 2002 and 2003 and
53% and 48% for the six-month periods ended June 30, 2002 and 2003,
respectively.

         SALES, GENERAL AND ADMINISTRATIVE EXPENSES. Sales, general and
administrative expenses consist primarily of salaries and related costs,
depreciation, amortization, legal and professional costs, rent, travel, and
advertising. Sales, general and administrative expenses increased 5% from
$585,775 to $613,944 for the three-month periods ended June 30, 2002 and 2003,
respectively. The increase resulted mainly from increased number of territory
representatives in the second quarter of 2003 as compared to the second quarter
of 2002. The decrease as a percentage of revenue is attributable to fixed
general and administrative costs compared to increased revenue. Sales, general
and administrative expenses increased 16% from $1,050,021 to $1,221,983 for the
six-month period ended June 30, 2002 and 2003, respectively. Sales, general and
administrative expenses as a percentage of revenue were 31% and 27% for the
three-month periods and 31% and 28% for the six-month periods ended June 30,
2001 and 2002, respectively.

         VARIABILITY OF FUTURE OPERATING RESULTS. The growth in quarterly
revenues was largely attributable to increased sales in sequencing services.
Although the Company expects higher and less variable revenue streams resulting
from the implementation of our business strategies, the ultimate success of
these changes cannot be reasonably predicted.

         LIQUIDITY AND CAPITAL RESOURCES. Operating cash flow was $543,330 and
$971,868 for the six-month periods ended June 30, 2002 and 2003, respectively.
This reflects an increase in operating cash flow of 79% for the six months ended
June 30, 2003 over the same six months ended June 30, 2002. The positive
operating cash flow for the period ending June 30, 2003 occurred mainly as a
result of net income of $969,946, offset by the increase in accounts receivable
invoices billed during the quarter. The Company utilized $396,766 in cash to
purchase all 222,902 outstanding shares of Common Stock from Takara Shuzo Co.,
Ltd.

         On February 28, 2003, the Company renewed its revolving line of credit
through December 31, 2003, and may continue to borrow up to $600,000 under the
terms of the credit line. As of June 30, 2003, there were no amounts outstanding
on this line and the Company was in compliance with all of the required
financial ratios for this facility.

         CONTRACTUAL OBLIGATIONS AND COMMERCIAL COMMITMENT. The following table
summarizes the Company's contractual obligations and commercial commitments as
of June 30, 2003 and the effect they are expected to have on its liquidity and
capital resources:

<Table>
<Caption>
Contractual                                          Less than                  After
Obligations                                Total       1 Year     1-3 Years    3 Years
-----------                              ----------   ---------   ----------   ----------
<S>                                     <C>          <C>         <C>          <C>
Revolving line of credit                $       --   $      --   $       --   $       --
Other credit facilities                         --          --           --           --
Capital lease obligations                1,267,389     570,974      696,415           --
Non-cancelable operating leases          1,066,047     192,744      328,111      545,192
                                        ----------   ---------   ----------   ----------
Total contractual obligations           $2,333,436   $ 763,718   $1,024,526   $  545,192
                                        ==========   =========   ==========   ==========
Other commercial commitments:
Revolving line of credit availability   $  600,000   $ 600,000   $       --   $       --
                                        ==========   =========    =========   ==========
</Table>


                                       8
<PAGE>


ITEM 3. CONTROLS AND PROCEDURES

(A)  Evaluation of disclosure controls and procedures

         Based on an evaluation of our disclosure controls and procedures as of
a date within 90 days of the filing date of this Quarterly Report on Form 10-Q,
our Chief Executive Officer and Chief Financial Officer have concluded that our
disclosure controls and procedures (as defined in Rules 13a-14(c) and 15d-14(c)
under the Securities Exchange Act of 1934 (the "Exchange Act")) are effective to
ensure that information required to be disclosed by us in reports that we file
or submit under the Exchange Act is recorded, processed, summarized and reported
within the time periods specified in Securities and Exchange Commission rules
and forms.

(B) Changes in internal controls

         There have been no significant changes in our internal controls or in
other factors that could significantly affect internal controls subsequent to
the date we carried out this evaluation.

                           PART II - OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

         None.

ITEM 2.  CHANGES IN SECURITIES

         None.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

         None.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

         None.

ITEM 5.  OTHER INFORMATION

         None.

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

         (A) Exhibits

Index of Exhibits

<Table>
<S>               <C>
         2.1(1)   The Agreement of Merger of November 18, 1994, between Lark
                  Technologies, Inc. and Lark Sequencing Technologies, Inc.
                  providing for the merger of Lark Sequencing Technologies, Inc.
                  into the Company.

         3.1(1)   Bylaws of Lark Technologies, Inc., as amended.

         3.2(1)   The Certificate of Incorporation of Lark Technologies, Inc.,
                  as amended.

         4.1(2)   Lark Technologies, Inc. 2000 Stock Option Plan adopted by the
                  Company.

         4.2(3)   Lark Technologies, Inc. 2002 Stock Option Plan adopted by the
                  Company.
</Table>


                                       9
<PAGE>


<Table>
<S>               <C>
        99.1      Certification of Chief Executive Officer and Chief Financial
                  Officer pursuant to 18 U.S.C. Section 1350, as adopted
                  pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
</Table>


(1) Incorporated by reference from the Company's Registration Statement on Form
S-4 dated August 14, 1995, Commission File No. 33-90424. The exhibit numbering
system used in Form S-4 differed from that used in this Form 10-QSB (8a, 2d, 2c,
6b, and 6f, respectively).

(2) Incorporated by reference from the Company's Registration Statement on Form
S-8 dated September 21, 2000, Commission File No. 333-46280.

(3) Incorporated by reference from the Company's Quarterly Report on Form 10-QSB
for the quarter ending September 30, 2002 filed November 5, 2002.

         (B) Reports on Form 8-K

A Form 8-K was filed on May 5, 2003 reporting the purchase by the company of
222,902 shares of Company Common Stock held by Takara Shuzo Co., Ltd. on May 2,
2003.



                                       10
<PAGE>


SIGNATURES


In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.


                                           Lark Technologies, Inc.
                                                 (Registrant)



Date August 12, 2003                              /s/ Carl Balezentis
--------------------                       ------------------------------------
                                                      Carl Balezentis
                                           President and Chief Executive Officer


                                       11
<PAGE>


CERTIFICATION

I, Carl W. Balezentis, President and Chief Executive Officer, certify that:

I have reviewed this quarterly report on Form 10-QSB of Lark Technologies, Inc.;

Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

Based on my knowledge, the financial statements, and other financial information
included in this quarterly report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this quarterly report;

The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

         designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this quarterly report is being prepared;

         evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and

         presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our evaluation
as of the Evaluation Date;

The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

         all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and

         any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and


The registrant's other certifying officers and I have indicated in this
quarterly report whether there were significant changes in internal controls or
in other factors that could significantly affect internal controls subsequent to
the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.


Date August 12, 2003                            /s/ Carl W. Balezentis
--------------------                       -------------------------------------
                                                    Carl W. Balezentis
                                           President and Chief Executive Officer



                                       12
<PAGE>


CERTIFICATION

I, Jon H. Luksich, Controller and Principal Financial Officer, certify that:

I have reviewed this quarterly report on Form 10-QSB of Lark Technologies, Inc.;

Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

Based on my knowledge, the financial statements, and other financial information
included in this quarterly report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this quarterly report;

The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

         designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this quarterly report is being prepared;

         evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and

         presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our evaluation
as of the Evaluation Date;

The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

         all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and

         any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and


The registrant's other certifying officers and I have indicated in this
quarterly report whether there were significant changes in internal controls or
in other factors that could significantly affect internal controls subsequent to
the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.


Date August 12, 2003                            /s/ Jon H. Luksich
--------------------                  ------------------------------------------
                                                    Jon H. Luksich
                                      Controller and principal financial officer


                                       13
<PAGE>



                                 EXHIBIT INDEX

<Table>
<Caption>
         EXHIBIT
           NO.                   DESCRIPTION
         -------                 -----------
<S>               <C>
         2.1(1)   The Agreement of Merger of November 18, 1994, between Lark
                  Technologies, Inc. and Lark Sequencing Technologies, Inc.
                  providing for the merger of Lark Sequencing Technologies, Inc.
                  into the Company.

         3.1(1)   Bylaws of Lark Technologies, Inc., as amended.

         3.2(1)   The Certificate of Incorporation of Lark Technologies, Inc.,
                  as amended.

         4.1(2)   Lark Technologies, Inc. 2000 Stock Option Plan adopted by the
                  Company.

         4.2(3)   Lark Technologies, Inc. 2002 Stock Option Plan adopted by the
                  Company.

        99.1      Certification of Chief Executive Officer and Chief Financial
                  Officer pursuant to 18 U.S.C. Section 1350, as adopted
                  pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
</Table>

(1) Incorporated by reference from the Company's Registration Statement on Form
S-4 dated August 14, 1995, Commission File No. 33-90424. The exhibit numbering
system used in Form S-4 differed from that used in this Form 10-QSB (8a, 2d, 2c,
6b, and 6f, respectively).

(2) Incorporated by reference from the Company's Registration Statement on Form
S-8 dated September 21, 2000, Commission File No. 333-46280.

(3) Incorporated by reference from the Company's Quarterly Report on Form 10-QSB
for the quarter ending September 30, 2002 filed November 5, 2002.